Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027158 | 0.85 | MAP2K1 (0.63) | MAP2K1KDM4EMAP2K2 | |
| SCHEMBL392120 | 0.81 | MAP2K1 (0.57) | MAP2K1MAP2K2LMNANPC1ALDH1A1 | |
| SCHEMBL27679456 | 0.78 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL1488379 | 0.78 | MAP2K1 (0.71) | MAP2K1MAP2K2LMNANPC1ALDH1A1 | |
| SCHEMBL27659429 | 0.76 | KEAP1 (0.50) | MAP2K1MAP2K2LMNANPC1ALDH1A1 | |
| SCHEMBL29413390 | 0.75 | KDM4C (0.51) | MAP2K1MAP2K2LMNANPC1ALDH1A1 | |
| SCHEMBL1488650 | 0.75 | KDM4C (0.51) | MAP2K1MAP2K2LMNANPC1ALDH1A1 | |
| SCHEMBL3974682 | 0.75 | MAP2K1 (0.53) | MAP2K1KDM4EMAP2K2 | |
| SCHEMBL2028212 | 0.74 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL3424609 | 0.74 | MAP2K1 (0.51) | MAP2K1KDM4EMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | claimed |
| EP-1802579-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-04 | — | — | EP | claimed |
| WO-2006045514-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-05-04 | — | — | WO | claimed |
| US-8841459-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2014-09-23 | — | — | US | disclosed |
| US-8841459-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2014-02-20 | — | — | US | disclosed |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2014-02-20 | — | — | US | disclosed |
| EP-1802579-B1 | Derivatives of 3-arylaminopyridine | MERCK SERONO SA (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8524911-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2013-09-03 | — | — | US | disclosed |
| US-8524911-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MERCK SERONO SA (CH) | 2011-09-15 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-7956191-B2 | 3-arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2011-06-07 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | MERCK SERONO SA (CH) | 2009-04-09 | — | — | US | disclosed |
| EP-1802579-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006045514-A1 | 3-ARYLAMINO PYRIDINE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224192-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | MAP2K1 105/4885KDM4E 797/4885MAP2K2 104/4885 |
| US-20120295889-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | MAP2K1 105/4885KDM4E 797/4885MAP2K2 104/4885 |
| US-20140051686-A1 | 3-Arylamino Pyridine Derivatives | MAPK3, BRAF, NRAS | MAP2K1 105/4885KDM4E 797/4885MAP2K2 104/4885 |
| US-20090093462-A1 | 3-Arylamino pyridine derivatives | CDK4, BRAF, CDK3 | MAP2K1 119/4885KDM4E 873/4885MAP2K2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.